DrugPatentWatch Database Preview

Details for Patent: 7,223,440

« Back to Dashboard

Which drugs does patent 7,223,440 protect, and when does it expire?

Patent 7,223,440 protects BYDUREON, BYDUREON PEN, and BYDUREON BCISE, and is included in two NDAs.

This patent has twenty-one patent family members in fourteen countries.

Summary for Patent: 7,223,440

Title:	Residual solvent extraction method and microparticles produced thereby
Abstract:	Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.
Inventor(s):	Rickey; Michael E. (Loveland, OH), Ramstack; J. Michael (Lunenburg, MA), Kumar; Rajesh (Marlborough, MA)
Assignee:	Alkermes, Inc. (Cambridge, MA)
Application Number:	11/312,371
Patent Claim Types: see list of patent claims	Formulation; Process; Use;

Drugs Protected by US Patent 7,223,440

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca Ab	BYDUREON	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-001	Jan 27, 2012		RX	Yes	Yes			Y
Astrazeneca Ab	BYDUREON PEN	exenatide synthetic	FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	022200-002	Feb 28, 2014		RX	Yes	Yes			Y
Astrazeneca Ab	BYDUREON BCISE	exenatide	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS	209210-001	Oct 20, 2017		RX	Yes	Yes			Y

International Family Members for US Patent 7,223,440

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	501711
Canada	2454027
Cyprus	1112348